Tissue Regenix achieves milestone in trials for key product

TISSUE Regenix today announced that it has hit an “important milestone” by gaining approval for the start of clinical trials for one of its skin products in treating acute wounds.

The York-based healthcare technology firm said that the trials were a step further towards it gaining access to a worldwide market for chronic and acute wound care worth an estimated $21bn.

The company said the clinical trials of its dCELL® dermis matrix in treating acute wounds will be carried out by University Hospital of South Manchester NHS Foundation Trust and will involve a series of six-week trials on 50 healthy human patients.

Tissue Regenix said that finding more effective ways to treat acute wounds, including surgical incisions and traumatic injuries such as lacerations, abrasions, avulsions, penetrations, bites or burn injuries, would save the NHS significant sums of money, improve patient recovery times and promote more successful healing.

The dCELL® dermis works by taking human donor skin and removing the DNA and cells, leaving a dermis matrix that can be placed over the wound to aid natural healing by attracting the patient’s own cells to the wound area.

Antony Odell, managing director of Tissue Regenix Group, commented: “We are delighted that this clinical trial can now proceed. Finding more effective ways to treat acute wounds could significantly improve the efficacy and speed of patient recovery times and save the NHS and other healthcare providers’ significant sums of money.

“This builds on the work we have already been undertaking in collaboration with Dr Bayat and his team in Manchester on chronic wounds, with a clinical study which investigated successfully the efficacy of Tissue Regenix dCELL® dermis matrix in healing chronic wounds such as venous ulcers.”

Close